Condition: Erythropoietin Adverse Reaction · Sponsor: Zealand University Hospital
The aim of the study is to 1. To determine whether treatment with Erythropoiesis-stimulating agents (in the form of Aranesp®) affects platelet function, and how. 2. To determine whether salicylate treatment changes the effect of EPO (erythropoietin) on platelet function.
This description comes directly from the study's public registry record.
Mette KOefoed, md · 0045 93576330 · mkof@regionsjaelland.dk
Rikke Borg, md, phd · rbor@regionsjaelland.dk
Always discuss trial participation with your own doctor first.
| Medicinsk afdeling, SUH Roskilde | Roskilde, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04330729